Page 2,549«..1020..2,5482,5492,5502,551..2,5602,570..»

eczema eyelid lotion – Video

Posted: Published on February 20th, 2015

eczema eyelid lotion This will help you. Get the product here: http://qps.ru/jkyvz. By: Dahsa Krypko … Continue reading →

Posted in Eczema | Comments Off on eczema eyelid lotion – Video

eczema eye lotion – Video

Posted: Published on February 20th, 2015

eczema eye lotion This will help you. Get the product here: http://qps.ru/jkyvz. By: Dahsa Krypko … Continue reading →

Posted in Eczema | Comments Off on eczema eye lotion – Video

IIFYM – Full Day of Eating with Ulcerative Colitis – Video

Posted: Published on February 20th, 2015

IIFYM - Full Day of Eating with Ulcerative Colitis Twitter: @rkannese. By: Rob Annese … Continue reading →

Posted in Ulcerative Colitis | Comments Off on IIFYM – Full Day of Eating with Ulcerative Colitis – Video

Buy Asacol online, the best treatment for ulcerative colitis – Video

Posted: Published on February 20th, 2015

Buy Asacol online, the best treatment for ulcerative colitis http://goo.gl/McmYWg. By: … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Buy Asacol online, the best treatment for ulcerative colitis – Video

Buy Asacol Online prevent ulcerative colitis – Video

Posted: Published on February 20th, 2015

Buy Asacol Online prevent ulcerative colitis http://goo.gl/McmYWg. By: … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Buy Asacol Online prevent ulcerative colitis – Video

Inflectra (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Posted: Published on February 20th, 2015

BARCELONA and MADRID, Spain (ots) - - Hungarian National Registry reports interim results following Inflectra therapy in 90 patients with Crohn's disease and ulcerative colitis - These data add to the growing body of evidence supporting the efficacy and safety of Inflectra treatment in inflammatory bowel disease Data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first approved biosimilar monoclonal antibody (mAb), at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference (https://www.ecco-ibd.eu/ecco15). Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade(R) (infliximab), for inducing and maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease (IBD). Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, (57 with CD and 33 with UC) treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment.[1]* C-reactive protein (CRP), a marker of inflammation, was also decreased during induction therapy for UC.[1] Four of the 90 patients showed an allergic reaction … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Inflectra (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Inflectra(TM) (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Posted: Published on February 20th, 2015

BARCELONA and MADRID, Spain (ots) - Data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first approved biosimilar monoclonal antibody (mAb), at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference (https://www.ecco-ibd.eu/ecco15). Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade(R) (infliximab), for inducing and maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease (IBD). Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, (57 with CD and 33 with UC) treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment.[1]* C-reactive protein (CRP), a marker of inflammation, was also decreased during induction therapy for UC.[1] Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti- TNF medication.[1] The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort ( https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/item/p314-biosimilar-infliximab-in-inflammatory-bowel-diseases-first-interim-results-from-a-prospective-nationwide-observational-cohort.html?highlight=YToxOntpOjA7czo0OiJwMzE0Ijt9 ). Professor Peter Lakatos, one of … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Inflectra(TM) (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

The American Epilepsy Society Announces Fellowship Award Recipients for 2015

Posted: Published on February 20th, 2015

Contact Information Available for logged-in reporters only Newswise West Hartford, Conn., February 19, 2015 The American Epilepsy Society (AES) has released its list of new fellowship awardees, naming 14 recipients for the organizations early-career awards. The fellowship recipients come from academic institutions and medical schools throughout the U.S. and include clinicians and basic scientists who are focused on many different components of epilepsy treatment and research. The winners were selected from a competitive pool of applicants. This years winners will receive funding for one year. The AES provides more than $700,000 to support research training grants for clinicians, research grants and pre- and post-doctoral research and training fellowships. Each year, AES clinical and basic science fellowship awardees are selected for their novel approaches to epilepsy care and research innovations that can help lead to new therapies and increase the understanding of epilepsy. Each year awardees bring new ideas and innovation to help increase our understanding of epilepsy and we are excited to see what 2015 will bring, said Kimford Meador, M.D., 2014 chair of the AES Research & Training Council. AESs commitment to funding young researchers at this critical stage in their career development helps assure that we will continue … Continue reading →

Comments Off on The American Epilepsy Society Announces Fellowship Award Recipients for 2015

Autism treatment by Homeopathy for a boy 5 years old – Video

Posted: Published on February 20th, 2015

Autism treatment by Homeopathy for a boy 5 years old By: David Grushko … Continue reading →

Comments Off on Autism treatment by Homeopathy for a boy 5 years old – Video

Growth Hormone Treatment Improves Social Impairments in Patients with Genetic Disorder Known to Cause Autism

Posted: Published on February 20th, 2015

Contact Information Available for logged-in reporters only Newswise (NEW YORK February 18) A growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome, according to a pilot study conducted at the Icahn School of Medicine at Mount Sinai and published today on Pub Med, a public database of biomedical topics maintained by the National Institutes of Health (study originally published in the December 12 issue of the journal Molecular Autism). The study results focus specifically on the use of insulin-like growth factor-1 (IGF-1) to treat Phelan-McDermid syndrome (PMS), a disorder caused by a deletion or mutation of the SHANK3 gene on chromosome 22. Along with facing developmental and language delays and motor skill deficits, most people with PMS also have autism spectrum disorder. SHANK3 is a focus of research in the field because of its essential role in the function of synapses, the gaps between nerve cells that decide whether messages continue along nerve pathways as they regulate bodily processes. While Phelan-McDermid syndrome is a rare disorder, advanced genetic technology has revealed it to be a relatively common cause of ASD. Ours is the first controlled trial of any … Continue reading →

Comments Off on Growth Hormone Treatment Improves Social Impairments in Patients with Genetic Disorder Known to Cause Autism

Page 2,549«..1020..2,5482,5492,5502,551..2,5602,570..»